The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
J | Antiinfectives for systemic use | |
2
|
J02 | Antimycotics for systemic use | |
3
|
J02A | Antimycotics for systemic use | |
4
|
J02AC | Triazole and tetrazole derivatives |
| Code | Title | |
|---|---|---|
| J02AC01 | Fluconazole | |
| J02AC02 | Itraconazole | |
| J02AC03 | Voriconazole | |
| J02AC04 | Posaconazole | |
| J02AC05 | ||
| J02AC06 |
| Active Ingredient |
|---|
|
Fluconazole is a triazole antifungal agent. Its primary mode of action is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. |
|
Isavuconazole is an active form of isavuconazonium. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cytoplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis. |
|
Itraconazole is a triazole derivative that inhibits fungal 14α-demethylase, resulting in a depletion of ergosterol and disruption of membrane synthesis by fungi. |
|
Posaconazole inhibits the enzyme lanosterol 14α-demethylase (CYP51), which catalyses an essential step in ergosterol biosynthesis. |
|
Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. |
| Document | Type | Information Source | |
|---|---|---|---|
| CRESEMBA Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) | |
| CRESEMBA Powder for concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| DIFLUCAN Hard capsule | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| DIFLUCAN Solution for infusion | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| DIFLUCAN Tablet / Oral suspension | MPI, US: SPL/Old | FDA, National Drug Code (US) | |
| FLUCORIC Capsule | MPI, Generic | Health Products Regulatory Authority (ZA) | |
| NOXAFIL Oral suspension | MPI, EU: SmPC | European Medicines Agency (EU) | |
| SPORANOX I.V. Concentrate and solvent for solution for infusion | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| VFEND Powder for solution | MPI, EU: SmPC | European Medicines Agency (EU) |